title: Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.
abstract: To obtain information about the functional importance of amino acids required for effective erythropoietin (EPO) mimetic action, the conserved residues of a peptide mimetic of EPO, recently discovered by phage display, were subjected to an alanine replacement strategy. Further, to identify a minimal mimetic peptide sequence, a series of truncation peptides has been generated. One EPO mimetic peptide sequence, EMP1, was targeted and more than 25 derivatives of this sequence were evaluated for their ability to compete with [125I]EPO for receptor binding and for their ability to support the proliferation of two EPO-responsive cell lines. Two hydrophobic amino acids, Tyr4 and Trp13, appear essential for mimetic action, and aromatic residues appear to be important at these sites. These findings are consistent with the previously reported X-ray crystal structure of EMP1 complexed with the extracellular domain of the EPO receptor (EPO binding protein; EBP). In our efforts to define the structural elements required for EPO mimetic action, a 13 amino acid peptide was identified which possesses mimetic properties and contains a minimal agonist epitope. The ability of this peptide to effectively serve as a mimetic capable of the induction of EPO-responsive cell proliferation appears to reside within a single residue, equivalent to position Tyr4 of EMP1, when present in a sequence that includes the cyclic core peptide structure. Although these peptides are less potent than EPO, they should serve as an excellent starting point for the design of compounds with EPO mimetic activity.
authors.affiliation: R. W. Johnson Pharmaceutical Research Institute, Drug Discovery Research, Raritan, New Jersey 08869, USA. djohnson@prius.jnj.com
authors.forename: D L
authors.initials: DL
authors.lastname: Johnson
authors.forename: F X
authors.initials: FX
authors.lastname: Farrell
authors.forename: F P
authors.initials: FP
authors.lastname: Barbone
authors.forename: F J
authors.initials: FJ
authors.lastname: McMahon
authors.forename: J
authors.initials: J
authors.lastname: Tullai
authors.forename: K
authors.initials: K
authors.lastname: Hoey
authors.forename: O
authors.initials: O
authors.lastname: Livnah
authors.forename: N C
authors.initials: NC
authors.lastname: Wrighton
authors.forename: S A
authors.initials: SA
authors.lastname: Middleton
authors.forename: D A
authors.initials: DA
authors.lastname: Loughney
authors.forename: E A
authors.initials: EA
authors.lastname: Stura
authors.forename: W J
authors.initials: WJ
authors.lastname: Dower
authors.forename: L S
authors.initials: LS
authors.lastname: Mulcahy
authors.forename: I A
authors.initials: IA
authors.lastname: Wilson
authors.forename: L K
authors.initials: LK
authors.lastname: Jolliffe
mesh_terms: D000409:Alanine / Q000502:physiology; D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000596:Amino Acids / Q000737:chemistry / Q000502:physiology*; D001667:Binding, Competitive; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004921:Erythropoietin / Q000138:chemical synthesis / Q000502:physiology*; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000502:physiology*; D017386:Sequence Homology, Amino Acid; D013329:Structure-Activity Relationship; D014443:Tyrosine / Q000502:physiology
chemical_list: D000596:Amino Acids; C099963:EPO mimetic peptide 1; D010456:Peptides, Cyclic; D004921:Erythropoietin; D014443:Tyrosine; D000409:Alanine